Age
Item
age 18 years or over
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Gender | Prior Chemotherapy Absent | Breast Carcinoma TNM Breast tumor staging
Item
female with newly diagnosed, not previously treated with chemotherapy, stage i-iii breast cancer
boolean
C0079399 (UMLS CUI [1])
C1514457 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0678222 (UMLS CUI [3,1])
C0474926 (UMLS CUI [3,2])
Chemotherapy cycle Adjuvant Quantity Planned | Chemotherapy cycle Neoadjuvant Quantity Planned
Item
planning to receive at least 4 cycles of adjuvant or neoadjuvant chemotherapy
boolean
C1302181 (UMLS CUI [1,1])
C1522673 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C1301732 (UMLS CUI [1,4])
C1302181 (UMLS CUI [2,1])
C0600558 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C1301732 (UMLS CUI [2,4])
Eligibility Medical Adjuvant Chemotherapy | Eligibility Medical Neoadjuvant Chemotherapy | pegfilgrastim
Item
medically eligible to safely receive adjuvant or neoadjuvant chemotherapy and pegfilgrastim as determined by the investigator
boolean
C1548635 (UMLS CUI [1,1])
C0205476 (UMLS CUI [1,2])
C0085533 (UMLS CUI [1,3])
C1548635 (UMLS CUI [2,1])
C0205476 (UMLS CUI [2,2])
C0600558 (UMLS CUI [2,3])
C3665472 (UMLS CUI [2,4])
C1136535 (UMLS CUI [3])
Prophylactic treatment Planned | pegfilgrastim
Item
planning to receive prophylaxis with pegfilgrastim starting in the first cycle and continuing throughout each chemotherapy cycle of the study period
boolean
C0199176 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
C1136535 (UMLS CUI [2])
Informed Consent
Item
has provided informed consent
boolean
C0021430 (UMLS CUI [1])
Comprehension DVD Materials
Item
able to understand the content of the dvd material, in investigator's opinion
boolean
C0162340 (UMLS CUI [1,1])
C4052484 (UMLS CUI [1,2])
C0520510 (UMLS CUI [1,3])
Able to read English Language | Comprehension English Language
Item
able to read and understand english
boolean
C0586740 (UMLS CUI [1,1])
C0376245 (UMLS CUI [1,2])
C0233733 (UMLS CUI [2,1])
C0376245 (UMLS CUI [2,2])
Chemotherapy Weekly Planned
Item
planning to receive weekly chemotherapy
boolean
C0392920 (UMLS CUI [1,1])
C0332174 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
NSAIDs Oral chronic | Antihistamines Oral chronic
Item
chronic use of oral nsaids or oral antihistamines with the following exception:
boolean
C0003211 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C0205191 (UMLS CUI [1,3])
C0019590 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205191 (UMLS CUI [2,3])
Exception | Aspirin Oral chronic Cardiovascular Diseases
Item
chronic oral aspirin use for cardiovascular-related indications
boolean
C1705847 (UMLS CUI [1])
C0004057 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205191 (UMLS CUI [2,3])
C0007222 (UMLS CUI [2,4])
Chronic pain | Condition Painful Treatment required for | Treatment Postoperative Pain | Treatment Post procedural pain
Item
ongoing chronic pain, or other painful conditions requiring treatment (including immediate post-operative treatment of surgical or procedural-associated pain) as determined by the investigator
boolean
C0150055 (UMLS CUI [1])
C0348080 (UMLS CUI [2,1])
C0030193 (UMLS CUI [2,2])
C0332121 (UMLS CUI [2,3])
C0087111 (UMLS CUI [3,1])
C0030201 (UMLS CUI [3,2])
C0087111 (UMLS CUI [4,1])
C0877303 (UMLS CUI [4,2])
Oral steroid therapy chronic | Premedication Relationship Taxanes allowed | Antiemetics allowed
Item
chronic oral steroid use. premedication related to the administration of taxanes, and use of anti-emetics is allowed, per usual clinical practice.
boolean
C0574135 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0033045 (UMLS CUI [2,1])
C0439849 (UMLS CUI [2,2])
C0796419 (UMLS CUI [2,3])
C0683607 (UMLS CUI [2,4])
C0003297 (UMLS CUI [3,1])
C0683607 (UMLS CUI [3,2])
Prior Chemotherapy Malignant Neoplasms
Item
prior chemotherapy treatment for cancer within 5 years of current breast cancer diagnosis
boolean
C1514457 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
G-CSF
Item
prior use of g-csf
boolean
C0079459 (UMLS CUI [1])
Study Subject Participation Status | G-CSF | Filgrastim | pegfilgrastim | GM-CSF | sargramostim
Item
currently enrolled in, or less than 30 days since ending, another clinical trial which includes language directing g-csf (filgrastim, pegfilgrastim, other) or gm-csf (sargramostim) use
boolean
C2348568 (UMLS CUI [1])
C0079459 (UMLS CUI [2])
C0210630 (UMLS CUI [3])
C1136535 (UMLS CUI [4])
C0079460 (UMLS CUI [5])
C0216231 (UMLS CUI [6])
Study Subject Participation Status | Blinded Clinical Study
Item
currently enrolled in, or less than 30 days since ending, another interventional clinical trial which includes a blinded treatment or blinded treatment arm (whether or not the subject is randomized to the blinded arm)
boolean
C2348568 (UMLS CUI [1])
C2347038 (UMLS CUI [2])
Study Subject Participation Status | Clinical Trial | Investigational New Drugs
Item
currently enrolled in, or less than 30 days since ending, another interventional clinical trial which includes the use of any agent not currently considered to be standard therapy for the adjuvant or neoadjuvant treatment of stage i-iii breast cancer based on nccn clinical practice guidelines in oncology for breast cancer
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2])
C0013230 (UMLS CUI [3])
Study Subject Participation Status | Pain Clinical Trial
Item
currently enrolled in, or less than 30 days since ending, any pain intervention study
boolean
C2348568 (UMLS CUI [1])
C0030193 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])